BMRA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.190

Open

2.100

VWAP

2.15

Vol

14.79K

Mkt Cap

6.55M

Low

2.100

Amount

31.85K

EV/EBITDA(TTM)

--

Total Shares

3.02M

EV

4.07M

EV/OCF(TTM)

--

P/S(TTM)

1.25

Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product, developed on the inFoods technology platform, is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.

Show More

Events Timeline

(ET)

2026-03-18

08:30:00

Biomerica Receives First Commercial Order for Hp Detect

2026-03-05 (ET)

2026-03-05

08:30:00

Biomerica Receives UK MHRA Registration for hp+detect Test

2026-02-26 (ET)

2026-02-26

08:30:00

Biomerica inFoods IBS Study Shows 59.4% Pain Relief Rate

2026-02-18 (ET)

2026-02-18

08:30:00

Biomerica's EZ Detect Test Approved for Sale in Vietnam

2025-12-23 (ET)

2025-12-23

08:30:00

Biomerica Announces $300 Medicare Payment Rate for inFoods IBS Test

2025-12-11 (ET)

2025-12-11

08:30:00

Biomerica Receives Authorization from Egyptian Drug Authority for Rapid Test Portfolio

2025-11-25 (ET)

2025-11-25

08:23:24

Biomerica's inFoods IBS Product Highlighted in Biotherapeutics Quarterly

2025-11-06 (ET)

2025-11-06

08:43:29

Biomerica Enhances CDMO Offerings to Address Increasing Market Demand

2025-10-16 (ET)

2025-10-16

08:20:53

Biomerica and Henry Schein Form Marketing Partnership for inFoods IBS Test

News

seekingalpha

03-18seekingalpha

Biomerica Secures First Commercial Order for Hp Detect Test

NASDAQ.COM

01-15NASDAQ.COM

Biomerica (BMRA) Reports Q2 Loss of $1.32 Million, Revenue Down 26.2%

seekingalpha

01-14seekingalpha

Biomerica (BMRA) Reports Q2 Net Loss of $1.32M, Revenue Down 26.2% YoY

Globenewswire

01-14Globenewswire

Biomerica (BMRA) Launches AI-Driven IBS Test Amid 4% Revenue Decline

Globenewswire

2025-12-23Globenewswire

Biomerica Announces $300 Medicare Payment for inFoods IBS Test

Globenewswire

2025-12-11Globenewswire

Biomerica Secures EDA Authorization for Multiple Cancer Screening Tests

Valuation Metrics

The current forward P/E ratio for Biomerica Inc (BMRA.O) is 0.00, compared to its 5-year average forward P/E of 12.72. For a more detailed relative valuation and DCF analysis to assess Biomerica Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

12.72

Current PE

0.00

Overvalued PE

45.88

Undervalued PE

-20.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.38

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.69

Undervalued EV/EBITDA

-0.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

2.26

Current PS

0.00

Overvalued PS

4.44

Undervalued PS

0.08

Financials

AI Analysis

Annual

Quarterly

Whales Holding BMRA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biomerica Inc (BMRA) stock price today?

The current price of BMRA is 2.17 USD — it has decreased -0.91

What is Biomerica Inc (BMRA)'s business?

Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product, developed on the inFoods technology platform, is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.

What is the price predicton of BMRA Stock?

Wall Street analysts forecast BMRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biomerica Inc (BMRA)'s revenue for the last quarter?

Biomerica Inc revenue for the last quarter amounts to 1.21M USD, decreased -26.04

What is Biomerica Inc (BMRA)'s earnings per share (EPS) for the last quarter?

Biomerica Inc. EPS for the last quarter amounts to -0.45 USD, increased 2.27

How many employees does Biomerica Inc (BMRA). have?

Biomerica Inc (BMRA) has 53 emplpoyees as of April 03 2026.

What is Biomerica Inc (BMRA) market cap?

Today BMRA has the market capitalization of 6.55M USD.